Aggregatibacter Actinomycetemcomitans, a Potent Immunoregulator of the Periodontal Host Defense System and Alveolar Bone Homeostasis
Overview
Microbiology
Authors
Affiliations
Aggregatibacter actinomycetemcomitans is a perio-pathogenic bacteria that has long been associated with localized aggressive periodontitis. The mechanisms of its pathogenicity have been studied in humans and preclinical experimental models. Although different serotypes of A. actinomycetemcomitans have differential virulence factor expression, A. actinomycetemcomitans cytolethal distending toxin (CDT), leukotoxin, and lipopolysaccharide (LPS) have been most extensively studied in the context of modulating the host immune response. Following colonization and attachment in the oral cavity, A. actinomycetemcomitans employs CDT, leukotoxin, and LPS to evade host innate defense mechanisms and drive a pathophysiologic inflammatory response. This supra-physiologic immune response state perturbs normal periodontal tissue remodeling/turnover and ultimately has catabolic effects on periodontal tissue homeostasis. In this review, we have divided the host response into two systems: non-hematopoietic and hematopoietic. Non-hematopoietic barriers include epithelium and fibroblasts that initiate the innate immune host response. The hematopoietic system contains lymphoid and myeloid-derived cell lineages that are responsible for expanding the immune response and driving the pathophysiologic inflammatory state in the local periodontal microenvironment. Effector systems and signaling transduction pathways activated and utilized in response to A. actinomycetemcomitans will be discussed to further delineate immune cell mechanisms during A. actinomycetemcomitans infection. Finally, we will discuss the osteo-immunomodulatory effects induced by A. actinomycetemcomitans and dissect the catabolic disruption of balanced osteoclast-osteoblast-mediated bone remodeling, which subsequently leads to net alveolar bone loss.
Peeran S, Fageeh H, Ibraheem W, Fageeh H, Al-Akhali M, Doggalli N J Pharm Bioallied Sci. 2025; 16(Suppl 5):S4667-S4677.
PMID: 40061785 PMC: 11888626. DOI: 10.4103/jpbs.jpbs_697_24.
Innovative biomaterials for the treatment of periodontal disease.
Zhu Y, Tao C, Goh C, Shrestha A Front Dent Med. 2025; 4:1163562.
PMID: 39916927 PMC: 11797777. DOI: 10.3389/fdmed.2023.1163562.
Di Spirito F, Pisano M, Caggiano M, De Benedetto G, Di Palo M, Franci G Children (Basel). 2025; 12(1).
PMID: 39857870 PMC: 11763593. DOI: 10.3390/children12010039.
Inflammation and immune response in the development of periodontal disease: a narrative review.
Lopez-Valverde N, Quispe-Lopez N, Blanco Rueda J Front Cell Infect Microbiol. 2024; 14:1493818.
PMID: 39679199 PMC: 11638196. DOI: 10.3389/fcimb.2024.1493818.
Experimental Inoculation of and and Its Impact on Alveolar Bone Loss and Oral and Gut Microbiomes.
Rocha C, Kawamoto D, Martins F, Bueno M, Ishikawa K, Ando-Suguimoto E Int J Mol Sci. 2024; 25(15).
PMID: 39125663 PMC: 11312116. DOI: 10.3390/ijms25158090.